IGKV3-11

Across TCGA pan-cancer cohorts, IGKV3-11 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGKV3-11 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher IGKV3-11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGKV3-11 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BRCA, PRAD, and LUAD are the cancer types where IGKV3-11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.313	0.924	<.001	36	view →
PRAD	OS	Median	All	0.145	0.883	<.001	12	view →
LUAD	DFS	Median	All	0.218	0.676	.014	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.559	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IGKV3-11–BRCA (OS)

Open the BRCA breakdown →